Embracing Personalization in Biopharma Patient Support Programs
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Fierce Pharma
APRIL 18, 2023
Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48
Fierce Pharma
OCTOBER 3, 2024
Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)
Fierce Pharma
FEBRUARY 27, 2024
Delivering on these heightened expectations has fueled the urgency to invest in patient engagement and support. A seismic shift has occurred in the healthcare landscape.
Fierce Pharma
JUNE 6, 2024
AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. lawmakers.
Fierce Pharma
SEPTEMBER 27, 2024
Patients with rare or complex diseases often struggle to find specialists who meet their specific condition and individual needs. Patients with rare or complex diseases struggle to find specialists who fit their unique needs, delaying crucial care. Digital tools can help.
Pharma IQ
JANUARY 22, 2025
Discover how advancements in unified systems, patient diversity, and regulatory submissions will accelerate drug development & improve patient outcomes.
pharmaphorum
DECEMBER 18, 2022
Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.
MedCity News
JULY 18, 2024
Expanded FDA approval of Phathom Pharmaceuticals drug Voquezna now includes patients with non-erosive gastroesophageal reflux disease (GERD). The post Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 19, 2023
With the right infrastructure, intelligent tools stand to not only process data but also improve clinical decision-making—helping find more patients for biopharma companies, and faster, too. Especially with the proliferation of AI in other industries and chatGPT.
Pharmaceutical Technology
SEPTEMBER 8, 2022
We have focused on PD-1-IL-2 as a biology that has great potential for benefiting patients.”. The post Roche to acquire biopharma firm Good Therapeutics for $250m appeared first on Pharmaceutical Technology. Subject to necessary clearance, the acquisition is anticipated to conclude in the third quarter of this year.
pharmaphorum
JUNE 27, 2022
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.
Fierce Pharma
MAY 9, 2024
A BIO survey of biopharma companies indicated that a sudden break-off from Chinese CDMOs could harm millions of patients. Innovent Biologics' GLP-1R/GCGR dual agonist, licensed from Eli Lilly, has notched a second positive phase 3 rea | Takeda launched a restructuring to achieve “organizational simplicity.” And more.
MedCity News
OCTOBER 27, 2023
Technology is transforming how clinical trials are run. A panel during MedCity News’ INVEST Digital Health conference discussed the tech trends shaping the design and execution of drug studies.
European Pharmaceutical Review
NOVEMBER 16, 2022
For young biotechs, scaling up production brings green-field challenges, while for more established pharma a shift may be required to ensure that facilities are optimised for new ways of working. That is because of the relative expense of emerging therapies and the pressure on pricing for continuing product lines.
Pharmaceutical Commerce
JUNE 17, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
Pharmaceutical Commerce
AUGUST 8, 2024
Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.
MedCity News
JULY 6, 2022
Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.
MedCity News
MARCH 18, 2024
As GenAI and other technologies advance the speed of development and the precision of drugs, pharma commercial teams need to make sure they are harvesting the right data with the right AI tools in order to ultimately reach the right patients.
Pharmaceutical Technology
JUNE 24, 2022
invoX Pharma has signed a definitive agreement for the acquisition of all issued and outstanding shares of clinical-stage biopharma firm F-star Therapeutics, in a deal valued at nearly $161m or $7.12 invoX Pharma is a fully owned Sino Biopharmaceutical subsidiary. for each share in cash.
European Pharmaceutical Review
DECEMBER 20, 2023
1 The changes form part of the 2020 Pharmaceutical Strategy for Europe will impact pharma and biopharma companies operating in Europe. The second is an adjustment of unmet need categorisation required for RDP extension; unmet need definition now encompasses ‘meaningful’ impact patient outcomes (notably including quality of life).
MedCity News
AUGUST 12, 2024
FDA approval of Ascendis Pharma’s Yorvipath is just in time for patients with hypoparathyroidism as Takeda Pharmaceutical will soon stop making the only drug therapy for the rare disorder. The post Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency appeared first on MedCity News.
MedCity News
FEBRUARY 14, 2024
2024 presents an exciting yet challenging landscape for global pharma marketers.
MedCity News
JUNE 27, 2024
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.
European Pharmaceutical Review
AUGUST 24, 2023
This strategy shift did not occur overnight, but evolved in response to the changing biopharma landscape. Even among the leaders of the biopharma sector, few companies have a significant presence across these platforms, Baral highlighted. Venture funding in 2022 came in at about $13.7 billion, down from the high of 2021.
Pharma Marketing Network
MARCH 25, 2022
Although the caregiver is seen as an extension of the patient and their role is not strictly defined, they are informal members of the front-line care team. 5 While the CDC gathers information on these topics for public health planning, there are immediate needs that pharma can address. . What Can Pharma Do? Sunny White.
pharmaphorum
JANUARY 9, 2023
Biopharma and healthcare group Chiesi Farmaceutici S.p.A. is to acquire the 2015-established Amryt Pharma Plc. He continued: “Amryt has steadily brought innovative products to new markets and, by adding them to the Chiesi portfolio, we hope to make them available to even more patients who may require them.”. on 6 th January.
pharmaphorum
NOVEMBER 28, 2022
Amidst all this, Adelphi Group’s CEO Stuart Cooper found a moment to sit with pharmaphorum web editor Nicole Raleigh and discuss just how exciting it was to bring to vibrant and discursive life the ethos of Anthropy – a united vision for British business, including pharma, and the future of this nation overall.
pharmaphorum
OCTOBER 11, 2022
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. The onus, he said, was on pharma to listen now. Patient engagement – what history teaches us about pharma’s future evolution. A one-on-one approach.
pharmaphorum
NOVEMBER 24, 2022
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Response rates above 50% in PD-1 high/intermediate patients with no liver tox surprises could set up for a potential acquisition.”
MedCity News
JANUARY 10, 2023
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
MedCity News
FEBRUARY 23, 2023
FDA approval of Sanofi hemophilia A drug Altuviiio provides patients with a therapeutic option that lasts longer than most other products available, including one already marketed by the French pharma giant. Altuviiio also gives Sanofi a way to better compete against blockbuster Roche drug Hemlibra.
MedCity News
DECEMBER 28, 2022
It fits in amongst the goal of running nimble and patient-centered studies. But, without legislation, it’s doubtful that pharma companies will give up ownership of participant data out of sheer goodwill. Putting data into the hands of participants is an important step in changing the traditional clinical trial paradigm.
MedCity News
JUNE 16, 2023
Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties.
MedCity News
APRIL 23, 2024
ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The post FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery appeared first on MedCity News. The novel immunotherapy works by sparking activity from three types of immune cells.
PM360
FEBRUARY 1, 2024
Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.
PM360
AUGUST 9, 2022
Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. For biopharma, success in this space will require integrated models that are significantly different than what has been used with historic medicines. In oncology, it’s 47% less.
MedCity News
OCTOBER 29, 2023
A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials. AI technologies have a role in the life sciences that goes beyond drug discovery.
MedCity News
SEPTEMBER 4, 2024
Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players.
European Pharmaceutical Review
AUGUST 28, 2024
Novartis Pharma AG and biotech Lindy Biosciences have agreed to collaborate to advance subcutaneous biologic injectables. This platform enables high concentrations of biologics to be delivered in a single dose, improving the convenience of administration and patient and treatment compliance, according to Lindy Biosciences. percent).
Clarivate
JUNE 29, 2023
We’re mindful of some challenges that life science and healthcare organizations must work through before this technology is mature enough for use in critical business decisions that may impact patient health. Our customers entrust our products and services to help them improve patient health, and we will not jeopardize that mission.
MedCity News
NOVEMBER 22, 2024
A patient death in a clinical trial usually prompts the FDA to impose a clinical hold. The post Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose appeared first on MedCity News.
MedCity News
APRIL 8, 2024
The expanded FDA approvals makes these cell therapies more accessible to more patients, broadening the market for both products. The post Cell Therapy Now Set to Reach More Patients With Expanded FDA Nod for 2 Multiple Myeloma Drugs appeared first on MedCity News.
PM360
SEPTEMBER 15, 2022
The term “patient centricity” has been around for over a decade, and since its first utterance the buzzword has been praised, dissected, criticized, and everything in between. The concept has always been worthwhile, but people within and outside of the industry have wondered whether the industry was truly becoming more patient centric?
MedCity News
MAY 11, 2023
Rexulti, a drug for schizophrenia and depression, now has an additional approval for treating agitation in Alzheimer’s disease patients. The FDA decision makes the Otsuka Pharmaceutical and Lundbeck product the first drug approved for this indication.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content